Serono in talks with top pharma companies about potential takeover

Share this article:
Serono has held talks with Novartis, GlaxoSmithKline, Sanofi-Aventis and Pfizer in recent weeks about a potential $15 billion takeover of the company, The Wall Street Journal reported today.
Serono, based in Geneva, Switzerland, is the world's third largest biotech company by sales.
In a statement, the company said that it has hired investment bank Goldman Sachs Group "to explore various strategic alternatives for the company," adding that "there can be no assurances that any transaction will be consummated."
Any buyer would most likely be interested in Serono's multiple sclerosis drug Rebif, which had sales of $1 billion in 2004. The company also sells drugs to treat infertility and is attempting to develop 30 new medicines for cancer, inflammatory diseases and other therapeutic areas.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.